English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/178601
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorMuedra, Vicentees_ES
dc.contributor.authorMoreno, Lucreciaes_ES
dc.contributor.authorRodilla, Vicentees_ES
dc.contributor.authorArce, Cristinaes_ES
dc.contributor.authorMontó, Fermíes_ES
dc.contributor.authorBlázquez, Águedaes_ES
dc.contributor.authorPérez, Palomaes_ES
dc.contributor.authorD’Ocón, Pilares_ES
dc.date.accessioned2019-03-27T08:01:15Z-
dc.date.available2019-03-27T08:01:15Z-
dc.date.issued2018-09-25-
dc.identifier.citationFontiers in Pharmacology 9:1014 (2018)es_ES
dc.identifier.urihttp://hdl.handle.net/10261/178601-
dc.description13 páginas, 6 figuras, 2 tablas.es_ES
dc.description.abstractIntroduction: Decreased antithrombin (AT) activity in patients scheduled for cardiovascular surgery under cardiopulmonary bypass (CPB) is related to increased postoperative complications and hospitalization time. Indirect evidence suggests that glucocorticoids mitigate this decreased AT activity. To better understand the beneficial effects of AT we have analyzed: (i) the clinical relevance of acute dexamethasone (DX) administration before cardiac surgery on AT activity, (ii) the modulation by DX of AT expression in human endothelial cells (hECs), (iii) the activity of AT on migration and angiogenesis of hECs, or on angiogenesis of rat aorta. Methods: A retrospective cohort study in patients undergoing aortic valve replacement surgery was designed to evaluate the effect of DX administration on AT activity at five separate time points: preoperatively, during CPB, at intensive care unit admission and at 12 and 24 h post-intervention. We have analyzed also clinical differences in postoperative outcomes as safety and the length of stay in hospitalization. Changes in mRNA levels of AT induced by DX were determined by qRT-PCR in human coronary (hCEC), aorta (hAEC) and cardiac microvasculature (hCMEC) endothelial cells. AT activity on migration and angiogenesis were also assayed. Angiogenic growth of rat aortic rings incubated in Matrigel® was determined in presence and absence of AT. Results: The cohort comprised 51 patients in the control group and 29 patients in the group receiving dexamethasone. Preoperative DX supplementation reduced intraoperative decrease of AT activity (67.71 ± 10.49% DX treated vs. 58.12 ± 9.11% untreated, p < 0.001) that could be related to a decrease in the hospitalization time (7.59 ± 4.08 days DX treated vs. 13.59 ± 16.00 days untreated, p = 0.014). Treatment of hECs with 500 nM DX slightly increased AT expression. Incubation with 0.5 and 1 IU/mL of AT increased migration and angiogenesis in hCAECs and hAECs, but not in hCMECs. The same concentrations of AT potentiated angiogenic sprouting of new vessels from rat aorta. Conclusion: Preoperative DX supplementation could be an interesting procedure to avoid excessive decrease in AT levels during cardiac surgery. Positive outcomes associated with maintaining adequate AT levels could be related to its potential beneficial effect on endothelial function (migration and angiogenesis).es_ES
dc.description.sponsorshipThis work (UGP-15-171) was supported by Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO) de la Comunitat Valenciana. Conselleria de Sanitat. Generalitat Valenciana.es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Mediaes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rightsopenAccesses_ES
dc.subjectAngiogenesises_ES
dc.subjectAntithrombines_ES
dc.subjectCardiac surgeryes_ES
dc.subjectCardiopulmonary bypasses_ES
dc.subjectDexamethasonees_ES
dc.subjectEndothelial functiones_ES
dc.titleDexamethasone Preconditioning in Cardiac Procedures Reduces Decreased Antithrombin Activity and Is Associated to Beneficial Outcomes: Role of Endotheliumes_ES
dc.typeartículoes_ES
dc.identifier.doi10.3389/fphar.2018.01014-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.3389/fphar.2018.01014es_ES
dc.identifier.e-issn1663-9812-
dc.rights.licenseCreative Commons Attribution License (CC BY)es_ES
dc.contributor.funderGeneralitat Valencianaes_ES
dc.relation.csices_ES
oprm.item.hasRevisionno ko 0 false*
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003359es_ES
dc.contributor.orcidPérez, Paloma [0000-0002-7166-2824]es_ES
Appears in Collections:(IBV) Artículos
Files in This Item:
File Description SizeFormat 
2018 Front Pharmacol 9-1014.pdf3,27 MBAdobe PDFThumbnail
View/Open
Show simple item record
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.